Hepion Pharmaceuticals, Inc. (CTRVP): Entry into a Material Definitive Agreement
Hepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 25, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell a
How this was made
The 30-second read
Why it matters
The filing provides the first public disclosure of the raise, confirming capital needs and potential dilution.
Market read
Micro‑cap biotech raise; low immediate trading relevance.
What to watch
Potential future dilution if additional raises occur; warrants extend dilution risk.
Background
SEC Form 8‑K filed by Hepion Pharmaceuticals detailing a private placement under Regulation D.
Ticker impact
Company filed an 8‑K announcing a private placement of 8 M shares and warrants at $0.05 per share, raising $400 k.
Minimal impact; price may stay flat or see slight uptick if demand exceeds supply.
Small raise size ($400k) for a micro‑cap; limited market depth and no strategic shift.
Market effects
Limited; micro‑cap biotech financing activity unchanged.
None; filing pertains only to the issuer.
Negligible.
Counterpoint
Investors may view the raise as a red flag for cash needs, suggesting short positions.
Key entities
- companyHepion Pharmaceuticals, Inc.
Issuer of the securities.
